Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 7/20 | 0.81 |
| ▸ | RET | P07949 | 14/20 | 0.64 |
| ▸ | KDR | P35968 | 11/20 | 0.64 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.62 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.62 |
| ▸ | SRC | P12931 | 4/20 | 0.62 |
| ▸ | ABL1 | P00519 | 3/20 | 0.62 |
| ▸ | EGFR | P00533 | 3/20 | 0.62 |
| ▸ | HCK | P08631 | 3/20 | 0.62 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.62 |
| ▸ | MTOR | P42345 | 3/20 | 0.62 |
| ▸ | EPHB4 | P54760 | 3/20 | 0.62 |
| ▸ | PRKDC | P78527 | 3/20 | 0.62 |
| ▸ | PLK4 | O00444 | 2/20 | 0.62 |
| ▸ | JAK2 | O60674 | 2/20 | 0.62 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.62 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.62 |
| ▸ | LCK | P06239 | 2/20 | 0.62 |
| ▸ | FYN | P06241 | 2/20 | 0.62 |
| ▸ | ROS1 | P08922 | 2/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12022201 | 0.96 | PIK3CD (0.87) | PIK3CDRETKDRPIK3CAPIK3CG | |
| SCHEMBL12422337 | 0.92 | PIK3CD (0.84) | PIK3CDRETKDRPIK3CAPIK3CG | |
| SCHEMBL12422304 | 0.92 | PIK3CD (0.84) | PIK3CDRETKDRPIK3CAPIK3CG | |
| SCHEMBL18922370 | 0.91 | PIK3CD (0.80) | PIK3CDRETKDRPIK3CAPIK3CG | |
| SCHEMBL12422336 | 0.91 | PIK3CD (0.82) | PIK3CDRETKDRPIK3CAPIK3CG | |
| SCHEMBL2199177 | 0.91 | PIK3CD (0.76) | PIK3CDRETKDRPIK3CAPIK3CG | |
| SCHEMBL12422364 | 0.90 | PIK3CD (1.00) | PIK3CDRETKDRPIK3CAPIK3CG | |
| SCHEMBL21082736 | 0.89 | PIK3CD (0.78) | PIK3CDRETKDRPIK3CAPIK3CG | |
| SCHEMBL12422381 | 0.87 | PIK3CD (0.85) | PIK3CDRETKDRPIK3CAPIK3CG | |
| SCHEMBL12422383 | 0.87 | PIK3CD (0.73) | PIK3CDRETKDRPIK3CAPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9828378-B2 | Kinase inhibitors and methods of use | INTELLIKINE LLC (US) | 2017-11-28 | — | — | US | disclosed |
| US-9828378-B2 | Kinase inhibitors and methods of use | INTELLIKINE LLC (US) | 2017-11-28 | — | — | US | disclosed |
| EP-3009436-A1 | KINASE INHIBITORS AND METHODS OF USE | Intellikine, LLC (US) | 2016-04-20 | — | — | EP | disclosed |
| US-20160024099-A1 | KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC | 2016-01-28 | — | — | US | disclosed |
| US-20160024099-A1 | KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC | 2016-01-28 | — | — | US | disclosed |
| EP-2313414-B1 | KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC (US) | 2015-11-04 | — | — | EP | disclosed |
| US-9096611-B2 | Kinase inhibitors and methods of use | INTELLIKINE LLC (US) | 2015-08-04 | — | — | US | disclosed |
| US-9096611-B2 | Kinase inhibitors and methods of use | INTELLIKINE LLC (US) | 2015-08-04 | — | — | US | disclosed |
| US-20110172228-A1 | KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC | 2011-07-14 | — | — | US | disclosed |
| US-20110172228-A1 | KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC | 2011-07-14 | — | — | US | disclosed |
| WO-2010006086-A2 | KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE, INC. (US) | 2010-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172228-A1 | KINASE INHIBITORS AND METHODS OF USE | PIK3CA, MTOR, PDPK1 | PIK3CD 6/4885RET 443/4885KDR 698/4885 |
| US-20160024099-A1 | KINASE INHIBITORS AND METHODS OF USE | PIK3CA, MTOR, PDPK1 | PIK3CD 6/4885RET 443/4885KDR 698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.